{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Landgren CO"],"funding":["NCI NIH HHS","Janssen Research and Development"],"pagination":["1840-1852"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7326703"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(7)"],"pubmed_abstract":["Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or die"],"journal":["Leukemia"],"pubmed_title":["Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)."],"pmcid":["PMC7326703"],"funding_grant_id":["P30 CA008748","P30 CA138292"],"pubmed_authors":["Voorhees P","Beksac M","Kuppens S","Hofmeister CC","Qi M","Jenner MW","Cavo M","Bandekar R","Moreau P","Spencer A","Williams C","Landgren CO","Estell JA","Chari A","Clemens PL","Neff T","van de Donk NWCJ","Goldschmidt H","Cohen YC","Heuck C","Sandhu I"],"additional_accession":[]},"is_claimable":false,"name":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).","description":"Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or die","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-05-09T00:32:12.443Z","creation":"2020-07-11T07:04:10Z"},"accession":"S-EPMC7326703","cross_references":{"pubmed":["32024950"],"doi":["10.1038/s41375-020-0718-z"]}}